Human B2M Knockout iPSC Derived Cardiomyocytes

Item number	Size	Datasheet	Manual	SDS	Delivery time	Quantity	Price
BPS-82541	1 vial		-	-	3 - 15 business days*		1,997.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

The Human B2M Knockout iPSC-Derived Cardiomyocytes are non-diseased, non-proliferative human... more

Close menu

Product information "Human B2M Knockout iPSC Derived Cardiomyocytes"

The Human B2M Knockout iPSC-Derived Cardiomyocytes are non-diseased, non-proliferative human cardiomyocytes differentiated from B2M Knockout iPS Cell Line (#82161). The iPS cell line was generated using CRISPR/Cas9 technology to remove B2M (Beta-2-Microglobulin) gene expression. The B2M-targeting CRISPR/Cas9 editing reagents were delivered via transduction with B2M (Human) CRISPR/Cas9 Lentivirus (Non-Integrating) (#78341).

Keywords:	CDABP0092,
Supplier:	BPS Bioscience
Supplier-Nr:	82541

Properties

Application:	B2M knockout assessment, iPSC derived cardiomyocyte function, cell therapy research/development
Species reactivity:	human

Database Information

KEGG ID :	K08055 \| Matching products
UniProt ID :	P61769 \| Matching products
Gene ID :	GeneID 567 \| Matching products

Handling & Safety

Storage:	Liquid nitrogen
Shipping:	-80°C (International: -80°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Human B2M Knockout iPSC Derived Cardiomyocytes"

Write a review